September 13, 2021

AACR Clinical Panel Series: Genitourinary Cancer

April 27, 2021

AACR Clinical Panel Series: Genitourinary Cancer


LARVOL is pleased to present a moderated discussion with top oncologists following AACR's Annual Meeting 2021. In the video below, Dr. Sandy Srinivas, Dr. Yousef Zakharia, and Kinisha Gala discuss the practice-changing impact of AACR presentations in genitourinary cancers.

On April 16, 2021 LARVOL hosted an oncology panel discussion on the top genitourinary cancer clinical trial abstracts presented during the American Association for Cancer Research (AACR) Annual Meeting 2021, held on April 10-15, 2021. LARVOL's Kinisha Gala moderated the discussion between GU KOLs Dr. Sandy Srinivas from Stanford University and Dr. Yousef Zakharia from the University of Iowa.

The discussion covered AACR abstract #LB004 Nivolumab (NIVO) and ipilimumab (IPI)treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial, AACR abstract #CT040 Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130, and AACR abstract #CT042 Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts)with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): updated overall survival (OS) from the randomized Phase III studyIMvigor130.


Highlights of this panel discussion included excitement at the prospect of immunotherapy for prostate cancer and an in-depth analysis into the status of immunotherapy in bladder cancer.

Watch this video for the full discussion:

Our AACR Panel Series covered five therapeutic areas including genitourinary cancer. Click below to read more about them and watch their video analysis.

Lung Cancer

Breast Cancer

Gastrointestinal Cancer

Hematological Malignancies

Download attached file

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.